Roche Inks $80M Upfront Deal for Hansoh’s Cancer ADC HS-20110
On October 17, 2025, Hansoh Pharmaceutical announced an exclusive worldwide licensing agreement (excluding Mainland China, Hong Kong, Macau, and Taiwan) with Roche for its investigational CDH17-targeting ADC, HS-20110, currently in a global Phase I trial for colorectal and other solid tumors3.
Roche will pay Hansoh an upfront payment of $80 million, with Hansoh eligible for additional development, regulatory, and commercialization milestone payments, as well as royalties on future sales31.
Total potential deal value (including milestones and royalties) could reach up to $1.45 billion, subject to clinical and commercial success2.
Under the terms, Roche gains the right to develop and commercialize HS-20110 in all markets outside Greater China, leveraging its global oncology infrastructure, while Hansoh retains rights in its core Greater China market31.
The partnership aims to accelerate HS-20110's development for unmet needs in solid tumors, combining Hansoh's innovative R&D with Roche's global clinical and commercial capabilities13.
Sources:
1. https://www.ainvest.com/news/hansoh-pharmaceutical-roche-strategic-alliance-catalyst-oncology-innovation-global-market-access-2510/
2. https://www.globalbankingandfinance.com/hansoh-cancer-roche-zero